NO328680B1 - Anvendelse av oral poliovirusvaksine (OPV) og ikke-polio enterovirusvaksine mot ikke-polio virussykdommer slik som type 1 diabetes og et vaksinepreparat omfattende nevnte virus. - Google Patents
Anvendelse av oral poliovirusvaksine (OPV) og ikke-polio enterovirusvaksine mot ikke-polio virussykdommer slik som type 1 diabetes og et vaksinepreparat omfattende nevnte virus. Download PDFInfo
- Publication number
- NO328680B1 NO328680B1 NO20016211A NO20016211A NO328680B1 NO 328680 B1 NO328680 B1 NO 328680B1 NO 20016211 A NO20016211 A NO 20016211A NO 20016211 A NO20016211 A NO 20016211A NO 328680 B1 NO328680 B1 NO 328680B1
- Authority
- NO
- Norway
- Prior art keywords
- vaccine
- serotypes
- enterovirus
- polio
- opv
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 151
- 241000709661 Enterovirus Species 0.000 title claims abstract description 106
- 208000000474 Poliomyelitis Diseases 0.000 title claims abstract description 88
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title claims abstract description 61
- 229940124867 Poliovirus vaccine Drugs 0.000 title claims abstract description 39
- 201000010099 disease Diseases 0.000 title claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 37
- 241000700605 Viruses Species 0.000 title abstract description 46
- 241000991587 Enterovirus C Species 0.000 title description 40
- 239000000203 mixture Substances 0.000 title description 5
- 229940031626 subunit vaccine Drugs 0.000 claims abstract description 24
- 230000036039 immunity Effects 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 230000001939 inductive effect Effects 0.000 claims description 15
- 241000709687 Coxsackievirus Species 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 241001466953 Echovirus Species 0.000 claims description 7
- 241000988559 Enterovirus A Species 0.000 claims description 7
- 230000001904 diabetogenic effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003999 initiator Substances 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 25
- 230000028993 immune response Effects 0.000 abstract description 25
- 230000002265 prevention Effects 0.000 abstract description 15
- 230000009931 harmful effect Effects 0.000 abstract description 7
- 230000002238 attenuated effect Effects 0.000 abstract description 6
- 230000002939 deleterious effect Effects 0.000 abstract description 2
- 229960005030 other vaccine in atc Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 43
- 238000002255 vaccination Methods 0.000 description 37
- 206010014909 Enterovirus infection Diseases 0.000 description 35
- 208000012022 enterovirus infectious disease Diseases 0.000 description 31
- 230000005867 T cell response Effects 0.000 description 25
- 241000709675 Coxsackievirus B3 Species 0.000 description 23
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 238000002649 immunization Methods 0.000 description 20
- 230000003053 immunization Effects 0.000 description 20
- 230000003472 neutralizing effect Effects 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 230000006698 induction Effects 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000005875 antibody response Effects 0.000 description 9
- 241000274177 Juniperus sabina Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 229940031551 inactivated vaccine Drugs 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000709701 Human poliovirus 1 Species 0.000 description 6
- 206010058874 Viraemia Diseases 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 201000009906 Meningitis Diseases 0.000 description 5
- 208000009525 Myocarditis Diseases 0.000 description 5
- 241000725643 Respiratory syncytial virus Species 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 230000008029 eradication Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 208000025223 poliovirus infection Diseases 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940029583 inactivated polio vaccine Drugs 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 241000709673 Coxsackievirus B4 Species 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 230000007108 local immune response Effects 0.000 description 3
- 229940041323 measles vaccine Drugs 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 230000001769 paralizing effect Effects 0.000 description 3
- 201000006995 paralytic poliomyelitis Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- 201000006219 Herpangina Diseases 0.000 description 2
- 241000709704 Human poliovirus 2 Species 0.000 description 2
- 241000709727 Human poliovirus 3 Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010035623 Pleuritic pain Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 108010048507 poliovirus receptor Proteins 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010061308 Neonatal infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 229940127241 oral polio vaccine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14087299P | 1999-06-24 | 1999-06-24 | |
| PCT/FI2000/000220 WO2001000236A1 (en) | 1999-06-24 | 2000-03-17 | Prevention of type 1 diabetes and other non-polio enterovirus diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20016211D0 NO20016211D0 (no) | 2001-12-18 |
| NO20016211L NO20016211L (no) | 2002-02-20 |
| NO328680B1 true NO328680B1 (no) | 2010-04-26 |
Family
ID=22493179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20016211A NO328680B1 (no) | 1999-06-24 | 2001-12-18 | Anvendelse av oral poliovirusvaksine (OPV) og ikke-polio enterovirusvaksine mot ikke-polio virussykdommer slik som type 1 diabetes og et vaksinepreparat omfattende nevnte virus. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1187631B1 (pt) |
| AT (1) | ATE276761T1 (pt) |
| AU (1) | AU770922B2 (pt) |
| CA (1) | CA2376923C (pt) |
| DE (1) | DE60014077T2 (pt) |
| DK (1) | DK1187631T3 (pt) |
| ES (1) | ES2228481T3 (pt) |
| NO (1) | NO328680B1 (pt) |
| PT (1) | PT1187631E (pt) |
| WO (1) | WO2001000236A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8961982B2 (en) * | 2005-12-16 | 2015-02-24 | The Regents Of The University Of California | Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer |
| FI20075063A0 (fi) * | 2007-02-01 | 2007-02-01 | Vactech Oy | Allergisen herkistymisen estäminen |
| FI20075861A0 (fi) | 2007-11-30 | 2007-11-30 | Vactech Oy | Enteroviruksen käyttö taudin diagnostiikassa, hoidossa ja ehkäisyssä |
| US20110245179A1 (en) * | 2008-09-17 | 2011-10-06 | Woo Jin Park | Composition for Prevention or Treatment of Heart Failure |
| EP2402029A1 (en) | 2010-07-01 | 2012-01-04 | Sanofi Pasteur | Enterovirus vaccines for preventing or treating type 1 diabetes (III) |
| EP2402028A1 (en) | 2010-07-01 | 2012-01-04 | Sanofi Pasteur | Enterovirus vaccines for preventing and treating type 1 diabetes (II) |
| ES2614251T3 (es) | 2010-07-01 | 2017-05-30 | Vactech Oy | Análisis de diagnóstico para diabetes tipo 1 |
| EP2402027A1 (en) | 2010-07-01 | 2012-01-04 | Sanofi Pasteur | Enterovirus vaccines for preventing or treating type 1 diabetes (I) |
| EP2583688A1 (en) | 2011-10-18 | 2013-04-24 | Sanofi Pasteur | Multi-CBV vaccine for preventing or treating type 1 diabetes |
| AU2012339560B2 (en) | 2011-11-18 | 2017-03-09 | Colin Dunlop | A method and apparatus for facilitating delivery of anaesthetic |
| US20140271718A1 (en) | 2013-03-15 | 2014-09-18 | University Of Florida Research Foundation Incorporated | Novel type 1 diabetes vaccines, and methods of use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728385A (en) * | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
-
2000
- 2000-03-17 AT AT00912706T patent/ATE276761T1/de active
- 2000-03-17 AU AU34366/00A patent/AU770922B2/en not_active Ceased
- 2000-03-17 WO PCT/FI2000/000220 patent/WO2001000236A1/en active IP Right Grant
- 2000-03-17 PT PT00912706T patent/PT1187631E/pt unknown
- 2000-03-17 ES ES00912706T patent/ES2228481T3/es not_active Expired - Lifetime
- 2000-03-17 DK DK00912706T patent/DK1187631T3/da active
- 2000-03-17 CA CA2376923A patent/CA2376923C/en not_active Expired - Fee Related
- 2000-03-17 EP EP00912706A patent/EP1187631B1/en not_active Expired - Lifetime
- 2000-03-17 DE DE60014077T patent/DE60014077T2/de not_active Expired - Lifetime
-
2001
- 2001-12-18 NO NO20016211A patent/NO328680B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20016211D0 (no) | 2001-12-18 |
| CA2376923A1 (en) | 2001-01-04 |
| CA2376923C (en) | 2014-08-05 |
| DK1187631T3 (da) | 2005-01-24 |
| DE60014077T2 (de) | 2005-10-20 |
| EP1187631B1 (en) | 2004-09-22 |
| ATE276761T1 (de) | 2004-10-15 |
| AU3436600A (en) | 2001-01-31 |
| DE60014077D1 (de) | 2004-10-28 |
| EP1187631A1 (en) | 2002-03-20 |
| PT1187631E (pt) | 2005-01-31 |
| WO2001000236A1 (en) | 2001-01-04 |
| AU770922B2 (en) | 2004-03-11 |
| ES2228481T3 (es) | 2005-04-16 |
| NO20016211L (no) | 2002-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pandey et al. | Vaccination strategies to combat novel corona virus SARS-CoV-2 | |
| Diaz-San Segundo et al. | Foot-and-mouth disease vaccines | |
| Foo et al. | Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide | |
| Lucero et al. | Norovirus vaccines under development | |
| RU2561595C2 (ru) | Вакцина против высокопатогенного репродуктивно-респираторного синдрома свиней (hp prrs) | |
| US7972592B2 (en) | Prevention of type 1 diabetes and other non-polio enterovirus diseases | |
| TWI686475B (zh) | 對抗腸病毒感染之基於腺病毒載體之疫苗 | |
| CA2977980A1 (en) | Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom | |
| Renukaradhya et al. | Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective | |
| Abdel-Moneim et al. | Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines | |
| AU2018411586A1 (en) | Attenuated flaviviruses | |
| Kristensen et al. | Efficacy and safety of simultaneous vaccination with two modified live virus vaccines against porcine reproductive and respiratory syndrome virus types 1 and 2 in pigs | |
| NO328680B1 (no) | Anvendelse av oral poliovirusvaksine (OPV) og ikke-polio enterovirusvaksine mot ikke-polio virussykdommer slik som type 1 diabetes og et vaksinepreparat omfattende nevnte virus. | |
| Zhang et al. | Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice | |
| Bello et al. | Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD) | |
| ES2748555T3 (es) | Vacuna contra la rinitis equina | |
| US10258685B2 (en) | Multi-CBV vaccine for preventing or treating type I diabetes | |
| EP4288526A1 (en) | Attenuated african swine fever virus and its use as a vaccine | |
| Wang et al. | Active inoculation with an inactivated Coxsackievirus A2 vaccine induces neutralizing antibodies and protects mice against lethal infection | |
| US20220023414A1 (en) | Prime-Boost Vaccination Regimen | |
| Zhang et al. | ASFV Subunit Vaccines: Strategies and Prospects for Future Development | |
| Bourne et al. | Control and eradication of human and animal diseases by vaccination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |